Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.NeoPharm, a biopharmaceutical company, has submitted a Phase II protocol to the FDA for the study of liposome entrapped docetaxel, a novel, liposomal delivery system of docetaxel, the active ingredient of Taxotere, in hormone refractory metastatic prostate cancer patients.
Subscribe to our email newsletter
Laurence Birch, president and CEO of NeoPharm, said: “The preliminary results from our Phase I trial, which has not yet concluded, have been encouraging. As a result, we plan to evaluate the efficacy of liposome entrapped docetaxel in prostate cancer patients who have failed radiation and hormonal treatment and we have submitted a Phase II protocol for such a study to the FDA.
“While FDA approval is needed before commencing patient enrollment, we believe this submission is yet another example of our commitment to progressing our drug product candidates through development.”